Dr. Yeshwanter Radhakrishnan, MD

Dr. Radhakrishnan practices at UVA University Medical Center in Charlottesville, Virginia.

Dr. Radhakrishnan's NPI, 1437635216, was assigned on July 16, 2018. Dr. Radhakrishnan holds Virginia license 0101280628.

Dr. Radhakrishnan's primary practice is UVA University Medical Center, at 1215 Lee St, Charlottesville, VA 22908 in Charlottesville City. The practice phone is (434) 760-3439.

Dr. Radhakrishnan's primary practice is UVA University Medical Center in Charlottesville, Virginia. Dr. Radhakrishnan is also affiliated with University Medical Center. The medical group on file is UVA Physicians Group. Dmand AI also links Dr. Radhakrishnan to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Radhakrishnan practices, 4 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Radhakrishnan's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dmand AI has Dr. Radhakrishnan's licenses on file in 2 states: Virginia and Minnesota.

CMS data shows 341 Medicare services from Dr. Radhakrishnan across 8 procedure codes in 2024, for 185 Medicare patients. Medicare paid $24,309 for them.

CMS counts 185 Medicare patients who saw Dr. Radhakrishnan in 2024. The largest group is 65 to 74, with 66 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 16% are also on Medicaid. Their average risk score is 2.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Radhakrishnan's median patient age at 61, with 50% women.

In 2024, Dr. Radhakrishnan wrote 227 Medicare Part D claims for 84 patients. 89% of them were for generic drugs. CMS names the drug for 88 of them, across 4 drugs with 11 or more claims each, at $1,373 in total drug cost. In 2023, CMS named 141 claims across 7 drugs.

Dr. Radhakrishnan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Radhakrishnan as offering telehealth.

Dmand AI links 19 papers to Dr. Radhakrishnan, published from 2019 to 2024. 2022 was the busiest year, with 5. The most frequent topics are Acute Kidney Injury, Continuous Renal Replacement Therapy and Renal Replacement Therapy. Dr. Radhakrishnan has published most often in Cleve Clin J Med. Dr. Radhakrishnan's most frequent co-authors are Wisit Cheungpasitporn, MD, Charat Thongprayoon, MD and Michael A. Mao, MD.

CMS Open Payments shows 10 general payments to Dr. Radhakrishnan from 3 drug and device companies from 2019 to 2025. Education make up the largest share, 52% of the total. Calliditas Therapeutics US Inc. paid the most, $82.